Salk Institute

Technologies Available for Licensing

Corticotropin-Releasing Factor (CRF) Antagonists

Inventors: Jean Rivier and Wylie Vale
Potential Uses: CNS, GI, Drug Discovery and Development
Drugs to activate CRF receptors based on peptide antagonists

The inventions relate to antagonists of the CRF hentetracontapeptides, as well as to members of the larger family of CRF-like peptides, to pharmaceutical compositions containing such CRF antagonists, and to methods of treating mammals using such CRF antagonists. CRF antagonists may be used to treat anxiety, depression, irritable bowel syndrome, immune suppression, Alzheimer's disease, hemorrhagic stress, drug addiction and withdrawal symptoms, and fertility problems. In addition, such CRF antagonists can provide the basis for valuable methods for drug screening in order to detect even more potent molecules that will bind to and/or activate CRF receptors.

Salk No: S96032
Patent Status: U.S. Patent No. 5,777,073 issued July 7, 1998
U.S. Patent No. 6,323,312 issued November 27, 2001
Publications: Brain Research 744:166-170 (1997)
J. Med. Chem. 41: 5002-5011 (1998)
J. Med. Chem. 41: 5012-5019 (1998)
J. Med. Chem. 42: 3175-3182 (1999)
J. Pharm. Exp. Ther. 290(2): 629-634 (1999)
License Terms: Exclusive, Partially Exclusive, Nonexclusive license negotiable
Contact: Michelle Booden, Ph.D., Director of Licensing, 858.453.4100 x1612, mbooden@salk.edu

Get Involved

Sign up for our email newsletter

Fill out my online form.
Contact
Salk Institute for Biological Studies
Street: 10010 N Torrey Pines Rd
City: La Jolla, CA 92037
Email: webrequest@salk.edu
Phone: 858.453.4100
Charity Navigator Rating
  • Salk Twitter
  • Salk LinkedIn
  • Salk Facebook
  • Salk Instagram
  • Salk Google+
  • Salk YouTube
  • Salk RSS Feed
© Copyright 2014 Salk Institute for Biological Studies About Scientists & Research News & Media Events Support